⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL29951194 | 0.98 | BLM (0.50) | — | |
| SCHEMBL15942710 | 0.82 | — | — | |
| SCHEMBL14944031 | 0.79 | TSHR (0.43) | — | |
| SCHEMBL13697266 | 0.76 | — | — | |
| SCHEMBL4561308 | 0.69 | TSHR (0.36) | — | |
| Hydrochloric Acid SCHEMBL17181764 | 0.68 | BLM (0.35) | — | |
| SCHEMBL28475397 | 0.68 | — | — | |
| SCHEMBL10970054 | 0.67 | — | — | |
| SCHEMBL9568927 | 0.67 | TSHR (0.72) | — | |
| SCHEMBL1709024 | 0.65 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12378224-B2 | Heteroaryl compounds and their use as Mer inhibitors | DONG-A SOCIO HOLDINGS CO., LTD. (KR) | 2025-08-05 | — | — | US | disclosed |
| US-12037346-B2 | Amino-substituted heteroaryls for treating cancers with EGFR mutations | NUVALENT, INC. (US) | 2024-07-16 | — | — | US | disclosed |
| US-12037346-B2 | Amino-substituted heteroaryls for treating cancers with EGFR mutations | NUVALENT, INC. (US) | 2024-07-16 | — | — | US | disclosed |
| CN-112778337-B | 3, 6 diazabicyclo [3.1.1] heptane derivatives as RET kinase inhibitors | 杭州邦顺制药有限公司 | 2023-09-26 | — | — | CN | disclosed |
| WO-2023133229-A2 | COMPOUNDS AND METHODS FOR MODULATING SPLICING | REMIX THERAPEUTICS INC. (US) | 2023-07-13 | — | — | WO | disclosed |
| US-20220340893-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2022-10-27 | — | — | US | disclosed |
| US-20220289732-A1 | HETEROCYCLIC WDR5 INHIBITORS AS ANTI-CANCER COMPOUNDS | NOVARTIS AG (CH) | 2022-09-15 | — | — | US | disclosed |
| US-11225655-B2 | Bi-functional complexes and methods for making and using such complexes | NUEVOLUTION A/S (DK) | 2022-01-18 | — | — | US | disclosed |
| WO-2022006543-A1 | 5-[5-(PIPERIDIN-4-YL)THIENO[3,2-C]PYRAZOL-2-YL]INDAZOLE DERIVATIVES AND RELATED COMPOUNDS AS MODULATORS FOR SPLICING NUCLEIC ACIDS AND FOR THE TREATMENT OF PROLIFERATIVE DISEASES | REMIX THERAPEUTICS INC. (US) | 2022-01-06 | — | — | WO | disclosed |
| EP-3523292-B1 | HETEROARYL COMPOUNDS AND THEIR USE AS MER INHIBITORS | DONG A SOCIO HOLDINGS CO LTD (KR) | 2021-12-15 | — | — | EP | disclosed |
| WO-2010118159-A1 | INHIBITORS OF FATTY ACID AMIDE HYDROLASE | INFINITY PHARMACEUTICALS, INC. (US) | 2010-10-14 | — | — | WO | disclosed |
| US-20100152196-A1 | Novel Fused Pyrrolocarbazoles | CEPHALON, INC. (US) | 2010-06-17 | — | — | US | disclosed |
| US-7671064-B2 | Fused pyrrolocarbazoles | CEPHALON, INC. (US) | 2010-03-02 | — | — | US | disclosed |
| US-20100041663-A1 | Organic Compounds as Smo Inhibitors | NOVARTIS AG | 2010-02-18 | — | — | US | disclosed |
| WO-2010007120-A1 | PYRIDAZINE DERIVATIVES AS SMO INHIBITORS | NOVARTIS AG (CH) | 2010-01-21 | — | — | WO | disclosed |
| US-7169802-B2 | Fused pyrrolocarbazoles | CEPHALON, INC. (US) | 2007-01-30 | — | — | US | disclosed |
| US-20060247294-A1 | Novel fused pyrrolocarbazoles | CEPHALON, INC. (US) | 2006-11-02 | — | — | US | disclosed |
| EP-1704148-A1 | NOVEL FUSED PYRROLOCARBAZOLES | CEPHALON, INC. (US) | 2006-09-27 | — | — | EP | disclosed |
| WO-2005063763-A1 | NOVEL FUSED PYRROLOCARBAZOLES | CEPHALON, INC. (US) | 2005-07-14 | — | — | WO | disclosed |
| US-20050143442-A1 | Novel fused pyrrolocarbazoles | CEPHALON, INC. | 2005-06-30 | — | — | US | disclosed |